ARTICLE | Clinical News
AMG 073: Began Phase III trial
December 24, 2001 8:00 AM UTC
Amgen Inc. (AMGN), Thousand Oaks, Calif. Product: AMG 073 Business: Metabolic Therapeutic category: Receptor agonist Target: Calcium-sensing receptor (CaR) Description: Second-generation small molecu...